A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer
- 1.4k Downloads
The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer.
Studies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. There were no language restrictions. After independent quality assessment and data extraction, data were pooled for meta-analysis.
Thirteen reports of randomized controlled trials (RCTs) were included for quality appraisal and data extraction. Ten reports were judged to be of fair quality and subjected to meta-analysis. A significant improvement in survival was associated with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) alone (hazard ratio [HR] = 0.60; 95% CI = 0.43 to 0.83; p = 0.002) or HIIC combined with early postoperative intraperitoneal chemotherapy (EPIC) (HR = 0.45; 95% CI = 0.29 to 0.68; p = 0.0002). There was a trend towards survival improvement with normothermic intraoperative intraperitoneal chemotherapy (p = 0.06), but this was not significant with either EPIC alone or delayed postoperative intraperitoneal chemotherapy. Intraperitoneal chemotherapy was also found to be associated with higher risks of intra-abdominal abscess (RR = 2.37; 95% CI = 1.32 to 4.26; p = 0.003) and neutropenia (RR = 4.33; 95% CI = 1.49 to 12.61; p = 0.007).
The present meta-analysis indicates that HIIC with or without EPIC after resection of advanced gastric primary cancer is associated with improved overall survival. However, increased risk of intra-abdominal abscess and neutropenia are also demonstrated.
KeywordsGastric carcinoma Intraperitoneal chemotherapy
All authors declare that there are no potential conflicts of interest. Tristan D. Yan, a surgical oncology research fellow, is partly sponsored by the Foundation for Applied Research in Gastrointestinal Oncology. The authors gratefully acknowledge Drs/Profs M. Ikeguchi, W. Yu, H. Rosen, L. Xin, Y. Yonemura, G. Wei and Z. Gao for providing advice or additional unpublished information regarding their respective trials. We thank Profs L. Xin and Y. Yonemura for translating studies published in Chinese and Japanese languages.
- 5.NHS Centre for Reviews and Dissemination. Undertaking Systemic Reviews of Research on Effectiveness: CRD’s Guidance for those Carrying Out or Commissioning Reviews. CRD Report 4 (2nd edn). York: NHS Centre for Reviews and Dissemination; 2001Google Scholar
- 13.Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. Hepatogastroenterol 2001;48:1776–82Google Scholar
- 14.Zhang W, Su D, Wang K, et al. Clinical study in prophylactic use of intraperitoneal hyperthermic chemoperfusion for the prevention of peritoneal metastasis in patients with advanced gastric carcinoma. Shanxi Yiyao Zazhi 1998;27:67–9Google Scholar
- 17.Miyashiro I, Furukawa H, Sasako M, et al. No survival benefit with adjuvant chemotherapy for serosal-positive gastric cancer: Randomised trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer - Japan Clinical Oncology Group 9206-2. Proc ASCO-GI 84 (abstr 4), 2005Google Scholar
- 21.Gao Z, Jiang Z, Zhou F. Clinical surgery of early intraperitoneal hyperthermic chemoperfusion for gastric cancer patients after operation. Zhonggou Zhongliu Linchuang 2002;29:294–5Google Scholar
- 24.Tan C, Wang X, Xu Y, et al. Study for prevention of peritoneal dissemination of advanced gastric cancer by intraperitoneal thermochemotherapy. Shiyong Zhongliu Zazhi 2000;15:165–7Google Scholar
- 26.Kaibara N, Hamazoe R, Iitsuka Y, et al. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterol 1989;36:75–8Google Scholar
- 33.Yu W, Sugarbaker P, Whang I. Randomised controlled trial of early postoperative intraperitoneal chemotherapy in gastric cancer: a preliminary report. Reg Cancer Treat 1994;2:90–3Google Scholar
- 36.Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955;159:1704–7Google Scholar
- 38.Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev CD005340, 2006Google Scholar
- 41.Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol doi:10.1245/s10434-006-9182-x, 2006Google Scholar
- 42.Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol doi:10.1093/annonc/mdl428, 2006Google Scholar
- 45.Cascinu S, Labianca R, Barone C, et al Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin and Epidoxorubibin in a randomized controlled trial. J Natl Cancer Inst doi: 10.1093/jnci/djk131, 2007Google Scholar